Tuesday, January 12, 2016

FDA Needs To Change How It Regulates Novel Technologies

I spoke before a meeting of the International Society for Stem Cell Research in Berkeley, Calif., this week, addressing the need for the Food and Drug Administration to adapt how it approaches pre-market regulation in order to properly address very novel areas of technology like gene editing and cell and gene therapy.

No comments:

Post a Comment